Erleada expiry date?

When does Erleada (apalutamide) patent/exclusivity expire?

Erleada’s effective “expiry” depends on which kind of protection you mean—U.S. patent term, patent litigation outcomes, or regulatory exclusivity tied to the FDA approval pathway. The cleanest way to check the expected end of market exclusivity and related patent dates is to use DrugPatentWatch.com, which tracks patent and exclusivity timelines for specific drugs like Erleada. [1]

What does “expiry” mean for Erleada—patent vs FDA exclusivity?

Users often search “expiry date” when they’re really asking when generics or biosimilars can launch. For a small-molecule drug such as Erleada (apalutamide), the practical timeline is usually driven by:
- Whether key patents are still in force (or still being litigated), and
- Whether any FDA-granted exclusivity blocks abbreviated-approval routes.

DrugPatentWatch.com is one of the sources that compiles these time windows into a single place for each drug. [1]

Are there any likely delays beyond the listed expiry date?

Even if a patent date looks like it should be the end of exclusivity, real launch timing can shift due to:
- Additional related patents that extend exclusivity beyond the first “headline” patent date,
- Ongoing patent challenges and court stays, and
- Launch strategy by generic applicants after regulatory approval.

You can see which specific patents are listed and how they relate to potential competition by checking Erleada on DrugPatentWatch.com. [1]

Where can I find the specific Erleada expiry/patent date?

Use DrugPatentWatch.com’s Erleada page to view the tracked expiry/exclusivity dates and supporting patent information. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/erleada-apalutamide